Novel Biomarkers in Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (1 October 2023) | Viewed by 12097
Special Issue Editors
Interests: pancreatic cancer; pancreatic surgery; hepatobiliary disease; liver surgery; mini invasive surgery, surgical oncology
Special Issues, Collections and Topics in MDPI journals
Interests: drug delivery; gene delivery; lipofection; lipid membranes; early cancer detection; magnetic levitation
Special Issues, Collections and Topics in MDPI journals
Interests: hepatobiliary-pancreatic surgery and cancers; abdominal surgical oncology; liver and pancreatic benign and chronic diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The identification of novel biomarkers is an urgent priority in pancreatic cancer management. From diagnosis to follow up and through to assessing responses to neoadjuvant and adjuvant treatments (e.g., radiotherapy, chemotherapy) and surgical resection, the availability of novel biomarkers could play a crucial role in the fight against this lethal disease.
The aim of this Special Issue is to collect the most relevant and recent findings in the field of the identification and development of novel biomarkers for pancreatic cancer. Furthermore, attention will be paid to contributions that highlight the potential role that novel biomarkers may have in guiding therapeutic decisions in the treatment of pancreatic cancer.
Research articles reflecting the fields of “in vitro” diagnostics and prognostics are welcome, as well as clinically applicable high-throughput diagnostic technologies that can provide oncologists with innovative companion diagnostics.
Dr. Damiano Caputo
Dr. Daniela Pozzi
Dr. Alessandro Coppola
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- biomarkers
- treatment response
- cancer prognosis
- early diagnosis
- cancer treatment
- pancreatic surgery
- chemotherapy
- radiotherapy
- technology